Xeljanz, also known by its generic name tofacitinib, is a relatively new product on the market. It was approved by the FDA in 2012, nearly a decade after the approval of Humira (adalimumab). Despite being a newcomer, Xeljanz may offer some more attractive points that appeal to patients. For those looking to alleviate symptoms of rheumatoid arthritis, Xeljanz does not require injections like Humira. Xeljanz is taken orally in pill form, which for some may be more convenient. Additionally, Xeljanz has shown lower rates of adverse reactions, like infections and anemia.
From a cost perspective, Xeljanz may be cheaper than Humira. A study conducted by the National Association of Managed Care found that Xeljanz was almost half the cost of Humira in 2019. However, the cost of a medication may vary depending on a person’s insurance coverage, the pharmacy, and the location.
Overall, both medications can reduce inflammation and pain associated with autoimmune diseases. While Humira has been around for longer, Xeljanz may be more appealing to patients due to factors such as a pill form, fewer side effects, and potentially a lower cost. Ultimately, the decision about which drug to take should be made with a doctor’s recommendation, taking into consideration a person’s individual condition and needs.
Article Created by A.I.